Once more, the CD44 protein, discussed in detail in the previous section, provides a remarkable example since radiolabeled antibodies directed against the CD44-v6 isoform appear to offer a promising therapeutic tool and are currently in clinical trials for treatment of head and neck cancer [99]. The gene discussed is CD44; the disease is head and neck cancer.